Cargando…
Development of an Organ-Directed Exosome-Based siRNA-Carrier Derived from Autologous Serum for Lung Metastases and Testing in the B16/BL6 Spontaneous Lung Metastasis Model
Exosomes are nano-sized extracellular vesicles that are known to carry various messages to distant cells. It was recently reported that cancer-derived exosomes are orientated to metastatic organs. However, there are no reports on drug carrier development using autologous serum-derived exosomes in vi...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9025519/ https://www.ncbi.nlm.nih.gov/pubmed/35456649 http://dx.doi.org/10.3390/pharmaceutics14040815 |
_version_ | 1784690892403113984 |
---|---|
author | Hazekawa, Mai Nishinakagawa, Takuya Hosokawa, Masato Ishibashi, Daisuke |
author_facet | Hazekawa, Mai Nishinakagawa, Takuya Hosokawa, Masato Ishibashi, Daisuke |
author_sort | Hazekawa, Mai |
collection | PubMed |
description | Exosomes are nano-sized extracellular vesicles that are known to carry various messages to distant cells. It was recently reported that cancer-derived exosomes are orientated to metastatic organs. However, there are no reports on drug carrier development using autologous serum-derived exosomes in vivo. The purpose of this study was to deliver therapeutic siRNAs for melanoma lung metastases using autologous serum-derived exosomes. Primary tumors were induced by subcutaneously injecting melanoma cells into the hindlimbs of female C57BL/6 mice. Primary tumors were surgically removed on day 14. On day 21 after tumor removal, lung metastases were evaluated. Exosomes were isolated from serum collected from mice on days 0, 3, 7, 10, and 14 after primary tumor inoculation. After isolating serum exosomes, siRNA-loaded exosomes were prepared. siRNA-loaded exosomes were intravenously injected into the B16/BL6 spontaneous lung metastasis model mice on days 0, 3, 7, and 10 after tumor removal. siRNA-loaded exosomes prepared with autologous serum-derived exosomes significantly decreased the number of metastatic lung colonies. Autologous serum-derived exosomes, which have high organ accumulation, could potentially be used as efficient carriers of therapeutic siRNAs for melanoma patients with lung metastases. |
format | Online Article Text |
id | pubmed-9025519 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-90255192022-04-23 Development of an Organ-Directed Exosome-Based siRNA-Carrier Derived from Autologous Serum for Lung Metastases and Testing in the B16/BL6 Spontaneous Lung Metastasis Model Hazekawa, Mai Nishinakagawa, Takuya Hosokawa, Masato Ishibashi, Daisuke Pharmaceutics Article Exosomes are nano-sized extracellular vesicles that are known to carry various messages to distant cells. It was recently reported that cancer-derived exosomes are orientated to metastatic organs. However, there are no reports on drug carrier development using autologous serum-derived exosomes in vivo. The purpose of this study was to deliver therapeutic siRNAs for melanoma lung metastases using autologous serum-derived exosomes. Primary tumors were induced by subcutaneously injecting melanoma cells into the hindlimbs of female C57BL/6 mice. Primary tumors were surgically removed on day 14. On day 21 after tumor removal, lung metastases were evaluated. Exosomes were isolated from serum collected from mice on days 0, 3, 7, 10, and 14 after primary tumor inoculation. After isolating serum exosomes, siRNA-loaded exosomes were prepared. siRNA-loaded exosomes were intravenously injected into the B16/BL6 spontaneous lung metastasis model mice on days 0, 3, 7, and 10 after tumor removal. siRNA-loaded exosomes prepared with autologous serum-derived exosomes significantly decreased the number of metastatic lung colonies. Autologous serum-derived exosomes, which have high organ accumulation, could potentially be used as efficient carriers of therapeutic siRNAs for melanoma patients with lung metastases. MDPI 2022-04-07 /pmc/articles/PMC9025519/ /pubmed/35456649 http://dx.doi.org/10.3390/pharmaceutics14040815 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Hazekawa, Mai Nishinakagawa, Takuya Hosokawa, Masato Ishibashi, Daisuke Development of an Organ-Directed Exosome-Based siRNA-Carrier Derived from Autologous Serum for Lung Metastases and Testing in the B16/BL6 Spontaneous Lung Metastasis Model |
title | Development of an Organ-Directed Exosome-Based siRNA-Carrier Derived from Autologous Serum for Lung Metastases and Testing in the B16/BL6 Spontaneous Lung Metastasis Model |
title_full | Development of an Organ-Directed Exosome-Based siRNA-Carrier Derived from Autologous Serum for Lung Metastases and Testing in the B16/BL6 Spontaneous Lung Metastasis Model |
title_fullStr | Development of an Organ-Directed Exosome-Based siRNA-Carrier Derived from Autologous Serum for Lung Metastases and Testing in the B16/BL6 Spontaneous Lung Metastasis Model |
title_full_unstemmed | Development of an Organ-Directed Exosome-Based siRNA-Carrier Derived from Autologous Serum for Lung Metastases and Testing in the B16/BL6 Spontaneous Lung Metastasis Model |
title_short | Development of an Organ-Directed Exosome-Based siRNA-Carrier Derived from Autologous Serum for Lung Metastases and Testing in the B16/BL6 Spontaneous Lung Metastasis Model |
title_sort | development of an organ-directed exosome-based sirna-carrier derived from autologous serum for lung metastases and testing in the b16/bl6 spontaneous lung metastasis model |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9025519/ https://www.ncbi.nlm.nih.gov/pubmed/35456649 http://dx.doi.org/10.3390/pharmaceutics14040815 |
work_keys_str_mv | AT hazekawamai developmentofanorgandirectedexosomebasedsirnacarrierderivedfromautologousserumforlungmetastasesandtestingintheb16bl6spontaneouslungmetastasismodel AT nishinakagawatakuya developmentofanorgandirectedexosomebasedsirnacarrierderivedfromautologousserumforlungmetastasesandtestingintheb16bl6spontaneouslungmetastasismodel AT hosokawamasato developmentofanorgandirectedexosomebasedsirnacarrierderivedfromautologousserumforlungmetastasesandtestingintheb16bl6spontaneouslungmetastasismodel AT ishibashidaisuke developmentofanorgandirectedexosomebasedsirnacarrierderivedfromautologousserumforlungmetastasesandtestingintheb16bl6spontaneouslungmetastasismodel |